Business Wire

Lightbits Labs Launches Industry’s First NVMe/TCP Clustered Storage Solution

11.12.2019 16:00:00 EET | Business Wire | Press release

Share

Lightbits Labs, the leader in NVMe™ over TCP (NVMe/TCP) software-defined disaggregated storage, today has advanced its software solution, LightOS, to deliver the first NVMe/TCP clustered storage solution.

With more companies moving away from direct attached storage (DAS), and with storage requirements typically growing far faster than compute requirements, both public-cloud providers and private-cloud builders are looking for ways to separate storage and compute so each can scale separately. One of the limiting factors to scaling disaggregated storage, however, is the need for high availability across clusters of storage and compute. Lightbits LightOS delivers the availability, flexibility and efficiency of hyperscale cloud infrastructure to on-premise data centers.

LightOS is now the first NVMe/TCP storage solution that protects against data loss and avoids service interruptions at scale. In the presence of server, storage, or network failures, LightOS maximizes operational efficiency, ensuring applications continue working in the presence of failures, and failover is handled automatically, keeping data fully consistent and available.

The average cost of IT downtime is enormous. According to Gartner, the average loss is $5,600 per minute. This can add up to more than half a million dollars lost per hour at the higher end.

“At cloud scale, everything fails, so we built LightOS to capture all the benefits of disaggregated storage while providing exceptional durability and availability to prevent service disruption,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs.

For cloud-native applications, access to available, performant and easily deployable infrastructure is key to business agility and application experience, at any scale - regardless of whether you deploy five nodes, five hundred nodes, or thousands of nodes.

Installed on commodity servers in large-scale data centers, LightOS is optimized for I/O intensive compute clusters, such as Cassandra, MySQL, MongoDB, and time series databases. With end-to-end NVMe, LightOS delivers high performance and consistently low latency. The result is a 10X increase in storage reliability and 50% decrease in total cost of ownership (TCO). As a standard-based, target-only solution that does not require installing any proprietary software on the client side, the ease of deployment at scale is unmatched. LightOS is built to run in your existing data center, requiring no changes to application servers or your network infrastructure, so that deploying it at scale is a breeze.

As LightOS provides highly available, flexible, and efficient disaggregated storage, application teams can focus their efforts on developing new services to achieve their business goals, while lowering spend and delivering high performance.

LightOS provides the following additional benefits:

  • Software-defined disaggregated storage for cloud data centers delivering similar performance as direct-attached NVMe SSDs and up to a 50% reduction in tail latency.
  • Independent scaling of storage and compute, driving better infrastructure utilization and efficiency and providing unparalleled flexibility.
  • Standards-based NVMe/TCP block storage access protocol for application servers to storage servers communication.
  • LightOS clusters leverage standard NVMe 1.4 multipathing and offers data replications on storage target side, which provides transparency to the client with quick failover.
  • Distributed and durable cluster management with fast failover handling.
  • No single point of failure in data and control paths.
  • Multiple LightOS clusters can exist in the same cloud data center and can be easily aggregated and managed as one large cloud-scale block storage solution.

Lightbits Labs Resources

For additional information, contact info@lightbitlabs.com

About Lightbits Labs™

Lightbits Labs, founded in 2016, is remaking modern cloud infrastructure on a global scale. The company’s mission is to reinvent the way storage and networking are conducted in data centers. As trailblazers in this field, its solutions are successfully being used in industry-leading private cloud and enterprise data centers around the globe. With strategic investors including Dell Technology Capital and Micron, and with investments from Chairman and co-founder Avigdor Willenz (Founder of Annapurna and Galileo), Lip-Bu Tan (CEO of Cadence and chairman of Walden International) and Marius Nacht (Co-Founder and Chairman of Check Point Software), Lightbits Labs is disaggregating storage and compute to improve performance and TCO. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marianne Dempsey
On behalf of Lightbits Labs
mdempsey@rainierco.com
508-475-0025 ext. 115

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye